Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00806013
Recruitment Status : Completed
First Posted : December 10, 2008
Last Update Posted : January 27, 2010
Information provided by:
Chinese Academy of Sciences

Brief Summary:
The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.

Condition or disease

Detailed Description:
Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.

Study Type : Observational
Actual Enrollment : 36 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study the Effects of CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide in Healthy Chinese Subject
Study Start Date : August 2008
Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Glipizide
U.S. FDA Resources

CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier

Biospecimen Retention:   Samples With DNA
The whole blood samples of each person are stored at -80℃.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 27 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Male Chinese subjects with different geontype of CYP2C9 and CYP2C19 were enrolled in this study. They are divided into three groups by different geontype.

Inclusion Criteria:

  • nonsmokers and in good health

Exclusion Criteria:

  • family history of diabetes mellitus
  • taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00806013

China, Liaoning
The second hospital to Liaoning University of TCM
Shenyang, Liaoning, China, 201203
Sponsors and Collaborators
Chinese Academy of Sciences
Principal Investigator: Bo Tan Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Additional Information: Identifier: NCT00806013     History of Changes
Other Study ID Numbers: SIMM-080601
First Posted: December 10, 2008    Key Record Dates
Last Update Posted: January 27, 2010
Last Verified: December 2008

Keywords provided by Chinese Academy of Sciences:

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs